Sunshine Heart Inc (CHFS) Receives Consensus Recommendation of “Strong Buy” from Analysts

Sunshine Heart Inc (NASDAQ:CHFS) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Analysts have set a 12-month consensus target price of $15.00 for the company, according to Zacks. Zacks has also given Sunshine Heart an industry rank of 184 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

Separately, Zacks Investment Research raised shares of Sunshine Heart from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research note on Wednesday, December 6th.

Shares of Sunshine Heart (NASDAQ:CHFS) traded down $0.21 during trading hours on Tuesday, reaching $4.07. 266,693 shares of the company’s stock traded hands, compared to its average volume of 521,501. Sunshine Heart has a 1 year low of $2.87 and a 1 year high of $68.20. The company has a market capitalization of $7.16, a P/E ratio of -0.03 and a beta of 2.31.

TRADEMARK VIOLATION NOTICE: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/sunshine-heart-inc-chfs-receives-consensus-recommendation-of-strong-buy-from-analysts.html.

About Sunshine Heart

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Get a free copy of the Zacks research report on Sunshine Heart (CHFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply